Actively Recruiting
Phase II Study of Naxitamab Plus GM-CSF with Induction Chemotherapy for Children and Young Adults Newly Diagnosed with High-Risk Neuroblastoma
Led by Shaare Zedek Medical Center · Updated on 2026-09-17
10
Participants Needed
1
Research Sites
200 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety of combining Naxitamab, an anti-GD2 antibody, with Childrens Oncology Group COG type induction chemotherapy in newly diagnosed patients with high-risk neuroblastoma. This Phase II trial builds on previous studies by replacing a similar antibody with Naxitamab, which has shown a favorable side effect profile and promising results. The goal is to study this chemoimmunotherapy approach in about 10 patients over two years. Participants will receive the standard COG type induction chemotherapy alongside Naxitamab and granulocyte-macrophage colony stimulating factor GM-CSF during induction cycles 1 through 5. Additional treatments such as consolidation, radiation, and post-consolidation therapies will be determined by the treating physician. The trial follows the St. Jude NB2012 protocol backbone, with Naxitamab replacing the prior anti-GD2 antibody to assess combined effects. Throughout the study, patients will have comprehensive assessments before enrollment, after two treatment cycles, and at the end of chemotherapy to evaluate response. Patients not achieving at least a partial response or showing disease progression will be removed from the study. Follow-up visits will occur after surgery and every four months for five years from diagnosis to monitor safety and disease status. The main outcomes measured include safety after treatment cycles and response rates at the end of induction therapy.
CONDITIONS
Brief Title
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
Research Team
D
Dr. Iris Fried
R
Rosi Goldenberg
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here